Global Actinic Keratosis Treatment market demand 2024, Forecast To 2033
27 Feb, 2024
The actinic keratosis treatment market size has exhibited strong growth in recent years, rising from $3 billion in 2023 to$3.24 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to factors such as treatment adherence, market competition, patient education initiatives, and advancements in dermatological practices, including research and clinical trials. The market anticipates continued robust growth, reaching $4.36 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. This growth is expected due to efforts in patient education and engagement, integration of digital health, increasing awareness, emphasis on preventive dermatology, and trends toward personalized medicine. Major trends projected for the forecast period include a shift towards combination therapies, technological advancements, personalized treatment approaches, the rise in incidence rates, and the adoption of minimally invasive treatments.
Global Actinic Keratosis Treatment Market Key Driver
The growing prevalence of actinic keratosis is expected to propel the growth of the actinic keratosis treatment market going forward. An actinic keratosis refers to a rough, scaly area of skin that appears as a result of years of exposure to the sun. Actinic keratosis treatment helps to identify and treat precancerous lesions by reducing their risk. Growing actinic keratosis prevalence leads to increased demand for actinic keratosis treatment products, potential medications in research, and recommendations for the use of topical treatments. For instance, in February 2022, according to the article by World Cancer Research Fund International, a UK-based organization, there were more than 150,000 new cases of actinic keratosis in 2020, which increased to 197,700 cases in 2022. Therefore, the growing prevalence of actinic keratosis drives the actinic keratosis treatment market. The 2023 market size for the actinic keratosis treatment market surged in response to the escalating prevalence of actinic keratosis cases globally. Furthermore, the market is anticipated to witness sustained growth in 2024 and 2028, supported by advancements in treatment modalities and rising awareness about skin health.
Get A Free Sample Of The Global Actinic Keratosis Treatment Market ReportGlobal Actinic Keratosis Treatment Market Segments
The global actinic keratosis treatment market covered in this report is segmented –
1) By Treatment: Topical Treatment, Procedural Modality, Photodynamic Therapy, Other Treatments
2) By Medication: Flurouracil Cream, Imiquimod Cream, Ingenol Mebutate Gel, Diclofenac Gel
3) By End User: Hospitals, Private Dermatology Clinics, Laser Therapy Centers, Cancer Treatment Centers, Spas and Rejuvenation Centers, Homecare
By Geography: The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa.
North America was the largest region in the actinic keratosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Actinic Keratosis Treatment Industry Players
Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline PLC, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals PLC, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company PLC, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.
Get The Full Global Actinic Keratosis Treatment Market Report
Actinic Keratosis Treatment Market Overview
Actinic keratoses treatment refers to a treatment done for actinic keratoses, a skin disease that appears on the face, scalp, backs of the hands, or chest as a result of sun exposure. This treatment decreases the risk of developing the skin condition by keeping the skin protected from ultraviolet (UV) rays and limiting regular exposure to the sun.
Actinic Keratosis Treatment Global Market Report 2023 provides data on the global actinic keratosis treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The actinic keratosis treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.